Komori
Semiannual Report4521KAKEN PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Semiannual Report — FY2026 H1

What KAKEN PHARMACEUTICAL CO.,LTD. reported for the period from 2026-04-01 to 2027-03-31.

How much it says
52Typical
What moved here
44named for the first time
Its own wording
37terms
Which filing this is
33/ 33newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist

During the interim consolidated accounting period, performance improved, with increases in revenue and profit resulting from the consolidation of 科研ベンチャーズ株式会社, established on 7 August 2026, receipt of milestone income under the licence agreement with J&J, insurance coverage for the wound-healing material silk elastin wound dressing, and the execution of sales partnership agreements. There were no material changes to the principal risks during the interim consolidated accounting period, and no significant changes to the assumptions underlying the business were indicated.

Komori's summary of this document, not the document's own words.
52Typical
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 37 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
73
Detailed
Magnitude of change
68
Detailed
Strategic shift
33
Thin
Capital movement
75
Very detailed
Disclosure gaps
15
Almost nothing
Future commitments
53
Typical
Risk changes
37
Thin
Finance and capital policy
31
Thin
Specificity of disclosure
60
Detailed
Product portfolio
79
Very detailed
Technology position
50
Typical
Confidence in strategic bets
R&D spend99億円Money spent making new things.
Cash left over-61億円Cash from the business, less what went into equipment.
Spent on equipmentNot disclosedThis document does not carry the figure.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.